Complete the SAD study and initiate a MAD study of VX-522
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 1 Aug 2023
- Due
- 31 Dec 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“the Company expects to complete the SAD and initiate a multiple ascending dose (MAD) study in 2023”
What we found
Evidence strength A What the grades mean
Later 10-K filings state that SAD dosing was completed and the MAD portion initiated in late 2023, within the stated 2023 window.
-
A Vertex Pharmaceuticals 8-K filed 2024-02-05
“Vertex completed dosing in the single ascending dose (SAD) portion of the Phase 1/2 study of VX-522 in people with CF.” ✓ confirmed on the page
-
A Vertex Pharmaceuticals 10-K filed 2024-02-15
“We completed dosing in the single ascending dose part of the clinical trial for VX-522 and initiated the multiple ascending dose part of the clinical trial in late 2023.” ✓ confirmed on the page
-
A Vertex Pharmaceuticals 10-K filed 2024-02-15
“At the end of 2023, we completed dosing in the single ascending dose part of the Phase 1/2 clinical trial for VX-522 in people with CF, and we initiated the multiple ascending dose part of the clinical trial.” ✓ confirmed on the page
Market reaction: the shares moved -2.1% against the S&P 500 over the three sessions around the disclosure (2 Feb 2024 to 7 Feb 2024). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- VX-522 SAD completion and MAD study initiation
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Vertex Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-VRTX-006530 · Corrections policy